Cyclooxygenase (also known as COX, Prostaglandin-endoperoxide synthase, Prostaglandin G/H synthase) is expressed in cells in three isoforms. COX-1 (constitutive) and COX-2 (inducible) isoforms catalyze the rate-limiting step of prostaglandin production.
Cyclooxygenase Inhibitors |
|
---|---|
Cat. No. | Product Name / Activity |
1706 | Acetaminophen |
Cyclooxygenase inhibitor; may be selective for COX-3 | |
4092 | Aspirin |
Cyclooxygenase inhibitor; NSAID | |
3786 | Celecoxib |
Selective cyclooxygenase-2 (COX-2) inhibitor | |
4454 | Diclofenac sodium salt |
Cyclooxygenase inhibitor; NSAID | |
1430 | DuP 697 |
Cyclooxygenase-2 (COX-2) inhibitor | |
4522 | Flufenamic acid |
Cyclooxygenase inhibitor; NSAID. Also activates TRPC6 | |
1507 | FR 122047 hydrochloride |
Cyclooxygenase (COX-1) inhibitor | |
1708 | Indomethacin |
Cyclooxygenase inhibitor (COX-1 > COX-2) | |
0942 | NS 398 |
Cyclooxygenase-2 (COX-2) inhibitor | |
1418 | Resveratrol |
Cyclooxygenase inhibitor | |
1550 | SC 560 |
Cyclooxygenase-1 (COX-1) inhibitor | |
3919 | SC 236 |
Selective cyclooxygenase-2 (COX-2) inhibitor | |
2580 | Tenidap |
NSAID, cyclooxygenase (COX-1) inhibitor. Also opener of KIR2.3 | |
4206 | Valdecoxib |
Selective and potent COX-2 inhibitor |
Cyclooxygenase (also known as COX, Prostaglandin-endoperoxide synthase, Prostaglandin G/H synthase) is expressed in cells in three isoforms: COX-1, COX-2 and COX-3. COX-1 (constitutive) and COX-2 (inducible) isoforms catalyze the rate-limiting step of prostaglandin production and are the targets of non-steroidal anti-inflammatory drugs. COX-3 does not appear to be involved in inflammatory processes, but seems to be involved in pain and fever. COX-3 is thought to be derived through the retention of the highly structured G + C-rich intron 1 of the COX-1 gene.
Tocris offers the following scientific literature for Cyclooxygenases to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.